These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 30370955)

  • 21. Rapid Complete Response to Single-Agent Bcl-2 Inhibitor Venetoclax in a Heart-Transplanted Patient with Triple Refractory Immunoglobulin Light-Chain Amyloidosis.
    Gran C; Borg Bruchfeld J; Ellin F; Nahi H
    Acta Haematol; 2020; 143(5):500-503. PubMed ID: 31896106
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low dose venetoclax in combination with bortezomib, daratumumab, and dexamethasone for the treatment of relapsed/refractory multiple myeloma patients-a single-center retrospective study.
    Regidor B; Goldwater MS; Wang J; Bujarski S; Swift R; Eades B; Emamy-Sadr M; Eshagian S; Schwartz G; Spektor TM; Berenson JR
    Ann Hematol; 2021 Aug; 100(8):2061-2070. PubMed ID: 33987683
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Carfilzomib, venetoclax and dexamethasone for relapsed/refractory multiple myeloma.
    Boccon-Gibod C; Talbot A; Le Bras F; Frenzel L; Royer B; Harel S; Lombion N; Belhadj K; Cuccuini W; Arnulf B
    Br J Haematol; 2020 May; 189(3):e73-e76. PubMed ID: 32012229
    [No Abstract]   [Full Text] [Related]  

  • 24. Long-term disease-free survival in a primary plasma cell leukemia treated by VAD, autologous PBSC transplantation, and IFN-alpha.
    Büchler T; Ferra C; Domingo A; Gallardo D; Sarra J; Grańena A
    Am J Hematol; 2002 Sep; 71(1):62. PubMed ID: 12221683
    [No Abstract]   [Full Text] [Related]  

  • 25. ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development.
    Cang S; Iragavarapu C; Savooji J; Song Y; Liu D
    J Hematol Oncol; 2015 Nov; 8():129. PubMed ID: 26589495
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myélome.
    Royer B; Minvielle S; Diouf M; Roussel M; Karlin L; Hulin C; Arnulf B; Macro M; Cailleres S; Brion A; Brechignac S; Belhadj K; Chretien ML; Wetterwald M; Chaleteix C; Tiab M; Leleu X; Frenzel L; Garderet L; Choquet S; Fuzibet JG; Dauriac C; Forneker LM; Benboubker L; Facon T; Moreau P; Avet-Loiseau H; Marolleau JP
    J Clin Oncol; 2016 Jun; 34(18):2125-32. PubMed ID: 27114594
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Apoptotic regulator BCL-2 blockade as a potential therapy in classical Hodgkin Lymphoma.
    Gamboa-Cedeño AM; Díaz M; Cristaldo N; Otero V; Schutz N; Fantl D; Cugliari S; Zerga M; Rojas-Bilbao E; Jauk F; García Rivello H; Nuñez M; Ranuncolo SM
    Life Sci; 2021 Mar; 268():118979. PubMed ID: 33421528
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Venetoclax for the treatment of multiple myeloma.
    Vaxman I; Sidiqi MH; Gertz M
    Expert Rev Hematol; 2018 Dec; 11(12):915-920. PubMed ID: 30428277
    [No Abstract]   [Full Text] [Related]  

  • 29. [Primary plasma cell leukemia (IgD-lambda) with hyperammonemia].
    Minauchi K; Fujie T; Matsubara N; Kasahara H; Ogura Y; Tamura M; Yamane Y; Tanaka M; Taneichi K
    Nihon Naika Gakkai Zasshi; 2004 Jan; 93(1):139-41. PubMed ID: 14968586
    [No Abstract]   [Full Text] [Related]  

  • 30. Venetoclax plus hypomethylating agents or low-dose cytarabine in acute myeloid leukemia: all that glitters is gold?
    Ferrara F
    Blood Cancer J; 2020 Jan; 10(1):10. PubMed ID: 31992691
    [No Abstract]   [Full Text] [Related]  

  • 31. Deep and sustained response after venetoclax therapy in a patient with very advanced refractory myeloma with translocation t(11;14).
    Touzeau C; Le Gouill S; Mahé B; Boudreault JS; Gastinne T; Blin N; Caillon H; Dousset C; Amiot M; Moreau P
    Haematologica; 2017 Mar; 102(3):e112-e114. PubMed ID: 28057737
    [No Abstract]   [Full Text] [Related]  

  • 32. Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma.
    Bajpai R; Sharma A; Achreja A; Edgar CL; Wei C; Siddiqa AA; Gupta VA; Matulis SM; McBrayer SK; Mittal A; Rupji M; Barwick BG; Lonial S; Nooka AK; Boise LH; Nagrath D; Shanmugam M
    Nat Commun; 2020 Mar; 11(1):1228. PubMed ID: 32144272
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia.
    Richard-Carpentier G; Jabbour E; Short NJ; Rausch CR; Savoy JM; Bose P; Yilmaz M; Jain N; Borthakur G; Ohanian M; Alvarado Y; Rytting M; Kebriaei P; Konopleva M; Kantarjian H; Ravandi F
    Clin Lymphoma Myeloma Leuk; 2020 Apr; 20(4):212-218. PubMed ID: 32035785
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Integrated Mechanistic Model of Minimal Residual Disease Kinetics With Venetoclax Therapy in Chronic Lymphocytic Leukemia.
    Gopalakrishnan S; Wierda W; Chyla B; Menon R; Miles D; Humerickhouse R; Awni W; Salem AH; Mensing S; Freise KJ
    Clin Pharmacol Ther; 2021 Feb; 109(2):424-432. PubMed ID: 32749675
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A case of allogeneic hematopoietic stem cell transplantation for primary plasma cell leukemia after treatment with daratumumab.
    Horisawa Y; Kondo T; Hishizawa M; Yamashita K; Takaori-Kondo A
    Ann Hematol; 2020 Nov; 99(11):2699-2701. PubMed ID: 32318778
    [No Abstract]   [Full Text] [Related]  

  • 36. Venetoclax plus daratumumab induce hematological CR and organ response in an AL amyloidosis patient with t(11;14).
    Ghilardi G; Stussi G; Mazzucchelli L; Röcken C; Rossi D; Gerber B
    Amyloid; 2019 Sep; 26(3):173-174. PubMed ID: 31232114
    [No Abstract]   [Full Text] [Related]  

  • 37. Pioneering apoptosis-targeted cancer drug poised for FDA approval.
    Mullard A
    Nat Rev Drug Discov; 2016 Mar; 15(3):147-9. PubMed ID: 26931080
    [No Abstract]   [Full Text] [Related]  

  • 38. The combination of venetoclax, daratumumab and dexamethasone for the treatment of refractory primary plasma cell leukemia.
    Nalghranyan S; Singh AP; Schinke C
    Am J Hematol; 2020 Feb; 95(2):E34-E35. PubMed ID: 31709578
    [No Abstract]   [Full Text] [Related]  

  • 39. Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia.
    Peirs S; Frismantas V; Matthijssens F; Van Loocke W; Pieters T; Vandamme N; Lintermans B; Dobay MP; Berx G; Poppe B; Goossens S; Bornhauser BC; Bourquin JP; Van Vlierberghe P
    Leukemia; 2017 Oct; 31(10):2037-2047. PubMed ID: 28074072
    [TBL] [Abstract][Full Text] [Related]  

  • 40. How do we manage t(11;14) plasma cell disorders with venetoclax?
    Chakraborty R; Bhutani D; Lentzsch S
    Br J Haematol; 2022 Oct; 199(1):31-39. PubMed ID: 35594184
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.